Description: 2021 Life Meeting - Session 5C: Assumption Setting in an Uncertain World 8.31.21 Recording

Description: 2021 ImpACT Conference - Session 14B: IFRS 17- Restructuring the Corporate Operating Model 10.29.21 Recording

Description: 2021 ImpACT Conference - Session 6C: Reshaping the Roles of Actuaries - A Case Study 10.27.21 Recording

Description: 2021 ImpACT Conference - Session 12C: The Evolving Role of Actuaries in a Principles-Based World 10.29.21 Recording

Description: In the time since the original proposal to move healthwriting companies from the blue blank to the orange blank, there have been several incremental updates to the blue blank by the NAIC Blanks Working Group to integrate portions of the orange blank into the blue blank. Meanwhile, the NAIC RBC Working Group has issued their proposal to change the health test for comment and appear to be moving forward with the proposal to revise the health test. This would obligate companies that write predominantly health business onto the orange blank rather than the blue blank, which they have historically used for reporting. Discover background of the revised health test, the incremental updates to the blue blank that have been implemented recently, additional incremental updates proposed for upcoming blue blanks, and the current status of the Health RBC Working Group proposal to revise the health test. Hear observations about companies that have opted to 'take the plunge' and move to the orange blank ahead of the revised health test as well as companies that have opted to remain on the blue blank and incrementally update as new requirements are integrated into the Blue blank. By attending the session, you will be able to: • Understand the context of the initiative to revise the NAIC health test. • Summarize the recent changes to the blue blank implemented by the Blanks Working Group that integrate portions of the orange blank into the blue blank. • Summarize the upcoming proposed changes to the blue blank by the Blanks Working Group that integrate additional portions of the orange blank into the blue blank. • Summarize the current status of the Health RBC Working Group proposal to revise the health test. • Provide industry perspective on companies that have opted to move to the orange blank ahead of the revised health test and companies that have opted to remain on the blue blank until the NAIC requires it.

Description: An increasingly common question in our industry is - what should actuaries be doing and what should IT be doing? This gets at the difference between the self-service model, where actuaries have minimal reliance on ITand the shared-service model, where IT is a partner that helps with goals such as developing capabilities and running production models. The presenters will cover the unique value proposition of actuarial and IT functions and use that context to explore the pros and cons of the two models. They will ask what is going to drive the operating model in the future, considering the implications of trends in governance, technology toolkit and company culture. The presentation will be followed by interactive discussions on three case studies related to how IT and actuarial teams can work together most effectively, allowing the group to learn what works and what doesn't work from other companies approaching these challenges.

Description: 2021 Life Meeting - Session 8F: Smaller Insurance Company Chief Actuary and Appointed Actuary Forum 9.1.21 Recording

Description: Join us for the Pandemics & Paradigm Shifts: ERM in an Intensely Dynamic World panel discussion, where industry and regulatory perspectives will help provide insight into a number of topics. Expect interactive dialogue opportunities based on the conversation between the panelists and the audience. Key topics that will be conversed about, but the panel is not limited to, include a brief review of historical paradigm shifts and subsequent insurer failures, best practices and an outlook on the ultra-dynamic world of today and consideration of a company's enterprise risk management framework as it affects ratings and insurance department examinations.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: After the arduous journeys IFRS 17 filers underwent to implement the standard, it would only make sense for insurers to seek the best return on their investment post effective date of 1/1/2023. Many insurers are now embarking a new phase of the journey that involves wrapping up any unfinished business as they might have taken a minimum compliance route to finish implementation and thinking about the knock-on effects the new standard has on the way they carry out business and perform financial reporting.